Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Charles River Laboratories International Inc Lowers FY 2013 Revenue Guidance; Reaffirms FY 2013 EPS Guidance


Wednesday, 1 May 2013 04:30pm EDT 

Charles River Laboratories International Inc announced that for fiscal 2013, it expects 3% to 5% topline growth and non-GAAP EPS of $2.80 to $2.90. The Company reported revenue of $1.142 billion in fiscal 2012. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $1.175 billion and EPS of $2.85 for fiscal 2013. 

Company Quote

60.04
-0.41 -0.68%
12:32pm EDT